Access the full text.
Sign up today, get DeepDyve free for 14 days.
Xuyang Jiao, Lin Zhao, Mengtao Ma, Xuefeng Bai, M. He, Yuanyuan Yan, Yan Wang, Qiuchen Chen, Xinnan Zhao, Mingyi Zhou, Zeshi Cui, Zhihong Zheng, E. Wang, M. Wei (2013)
MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)Breast Cancer Research and Treatment, 139
H. Kanamaru, Yoshiyuki Kakehi, Osamu Yoshida, Shigetada Nakanishi, I. Pastan, M. Gottesman (1989)
MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants.Journal of the National Cancer Institute, 81 11
J. Fletcher, M. Haber, M. Henderson, M. Norris (2010)
ABC transporters in cancer: more than just drug efflux pumpsNature Reviews Cancer, 10
O. Bruhn, I. Cascorbi (2014)
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevanceExpert Opinion on Drug Metabolism & Toxicology, 10
B. Beuselinck, A. Karadimou, D. Lambrechts, B. Claes, P. Wolter, G. Couchy, J. Berkers, R. Paridaens, P. Schöffski, A. Méjean, V. Verkarre, E. Lerut, A. Taille, J. Tourani, P. Bigot, C. Linassier, S. Négrier, J. Berger, J. Patard, J. Zucman‐Rossi, S. Oudard (2013)
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinibBritish Journal of Cancer, 108
S. Holm (1979)
A Simple Sequentially Rejective Multiple Test ProcedureScandinavian Journal of Statistics, 6
K. Natarajan, Yi Xie, M. Baer, D. Ross (2012)
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.Biochemical pharmacology, 83 8
P. Fisel, V. Stühler, J. Bedke, S. Winter, S. Rausch, J. Hennenlotter, A. Nies, A. Stenzl, M. Scharpf, F. Fend, S. Kruck, M. Schwab, E. Schaeffeler (2015)
MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinomaOncotarget, 6
Moritz Oberstadt, Sandra Bien-Möller, K. Weitmann, Susann Herzog, Katharina Hentschel, C. Rimmbach, S. Vogelgesang, Ellen Balz, Matthias Fink, H. Michael, J. Zeden, Henrike Bruckmüller, A. Werk, I. Cascorbi, W. Hoffmann, D. Rosskopf, H. Schroeder, H. Kroemer (2013)
Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiformeBMC Cancer, 13
Lixia Lv, Xiu-mei An, Hongyan Li, Lan‐lan Ma (2016)
Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells.Oncology letters, 11 2
Claudia Neul, E. Schaeffeler, A. Sparreboom, S. Laufer, M. Schwab, A. Nies (2016)
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors.Trends in pharmacological sciences, 37 11
O. Woodward, A. Köttgen, J. Coresh, E. Boerwinkle, W. Guggino, M. Köttgen (2009)
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing goutProceedings of the National Academy of Sciences, 106
S. Haenisch, A. Werk, I. Cascorbi (2014)
MicroRNAs and their relevance to ABC transporters.British journal of clinical pharmacology, 77 4
B. Beuselinck, S. Job, E. Becht, A. Karadimou, V. Verkarre, G. Couchy, Nicolas Giraldo, N. Rioux-Leclercq, V. Molinie, M. Sibony, R. Elaidi, C. Teghom, J. Patard, A. Méjean, W. Fridman, C. Sautès-Fridman, A. Reyniès, S. Oudard, J. Zucman‐Rossi (2015)
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic SettingClinical Cancer Research, 21
J. Diestra, G. Scheffer, I. Catalá, M. Maliepaard, J. Schellens, R. Scheper, J. Germá-Lluch, M. Izquierdo (2002)
Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded materialThe Journal of Pathology, 198
R. Robey, Kenneth To, O. Polgar, M. Dohse, P. Fetsch, M. Dean, S. Bates (2009)
ABCG2: a perspective.Advanced drug delivery reviews, 61 1
Turner (2006)
ABCG2 expression, function, and promoter methylation in human multiple myelomaBlood, 108
Yuzhuo Pan, M. Morris, A. Yu (2009)
MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer CellsMolecular Pharmacology, 75
K. To, Wing-Wah Leung, S. Ng (2017)
A novel miR‐203‐DNMT3b‐ABCG2 regulatory pathway predisposing colorectal cancer developmentMolecular Carcinogenesis, 56
Eran Bram, M. Stark, Shachar Raz, Y. Assaraf (2009)
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.Neoplasia, 11 12
I. Hauser, S. Kruck, S. Gauer, A. Nies, A. Nies, S. Winter, S. Winter, Jens Bedke, H. Geiger, H. Höfeld, J. Kleemann, A. Asbe-Vollkopf, Juergen Engel, O. Burk, O. Burk, M. Schwab, E. Schaeffeler, E. Schaeffeler (2012)
Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal TransplantationClinical Pharmacology & Therapeutics, 91
R. Robey, Kristen Pluchino, M. Hall, A. Fojo, S. Bates, M. Gottesman (2018)
Revisiting the role of ABC transporters in multidrug-resistant cancerNature Reviews Cancer, 18
Kenneth To, R. Robey, T. Knutsen, Z. Zhan, T. Ried, S. Bates (2009)
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2Molecular Cancer Therapeutics, 8
Sheldon, W., Tobe, Sandra, E., Noble-Topham, Irene, L., Andrulis, R., Warren, J., Hartwick, Karl, Skorecki, Ellen, Warner (1995)
Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 12
(2016)
R Foundation for Statistical Computing
Namisaki (2014)
Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinomaDrug Metab Dispos, 42
P. Fisel, S. Kruck, S. Winter, J. Bedke, J. Hennenlotter, A. Nies, M. Scharpf, F. Fend, A. Stenzl, M. Schwab, E. Schaeffeler (2013)
DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical OutcomeClinical Cancer Research, 19
M. Siegsmund, U. Brinkmann, Elke Scháffeler, G. Weirich, M. Schwab, M. Eichelbaum, P. Fritz, O. Burk, J. Decker, P. Alken, U. Rothenpieler, R. Kerb, S. Hoffmeyer, H. Brauch (2002)
Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors.Journal of the American Society of Nephrology : JASN, 13 7
Xin Li, Yuzhuo Pan, G. Seigel, Ziyu Hu, Min Huang, A. Yu (2011)
Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.Biochemical pharmacology, 81 6
W. Rui, F. Bing, Hai-zhu Song, De Wei, Long-Bang Chen (2009)
Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1)Journal of Cellular and Molecular Medicine, 14
M. Huls, Colin Brown, A. Windass, R. Sayer, J. Heuvel, S. Heemskerk, F. Russel, R. Masereeuw (2008)
The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.Kidney international, 73 2
G. Hofmockel, I. Bassukas, A. Wittmann, J. Dämmrich (1997)
Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer?British journal of urology, 80 1
S. Winter, P. Fisel, F. Büttner, S. Rausch, Debora D’Amico, J. Hennenlotter, S. Kruck, A. Nies, A. Stenzl, K. Junker, M. Scharpf, U. Hofmann, Heiko Kuip, F. Fend, G. Ott, A. Agaimy, A. Hartmann, J. Bedke, M. Schwab, E. Schaeffeler (2016)
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenesScientific Reports, 6
Hiromi Wettersten, Omran Aboud, P. Lara, R. Weiss (2017)
Metabolic reprogramming in clear cell renal cell carcinomaNature Reviews Nephrology, 13
F. Büttner, S. Winter, S. Rausch, A. Reustle, S. Kruck, K. Junker, A. Stenzl, A. Agaimy, A. Hartmann, J. Bedke, M. Schwab, E. Schaeffeler (2015)
Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron.European urology, 68 6
N. Gupta, Pamela Martin, S. Miyauchi, S. Ananth, Anne Herdman, R. Martindale, R. Podolsky, V. Ganapathy (2006)
Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.Biochemical and biophysical research communications, 343 2
(2004)
Articles on similar topics can be found in the following Blood collections Gene Expression (1086 articles)
Partha Krishnamurthy, J. Schuetz (2011)
The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival.Current pharmaceutical biotechnology, 12 4
Kenneth To, Z. Zhan, S. Bates (2006)
Aberrant Promoter Methylation of the ABCG2 Gene in Renal CarcinomaMolecular and Cellular Biology, 26
R. Team (2014)
R: A language and environment for statistical computing.MSOR connections, 1
L. Morbidelli, S. Donnini, M. Ziche (2004)
Role of nitric oxide in tumor angiogenesis.Cancer treatment and research, 117
M. Diekstra, J. Swen, E. Boven, D. Castellano, H. Gelderblom, R. Mathijssen, C. Rodríguez‐Antona, J. García-Donas, B. Rini, H. Guchelaar (2015)
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.European urology, 68 4
Hongwei Liu, Zhixiong Liu, B. Jiang, L. Huo, Jinfang Liu, Jingchen Lu (2015)
Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in GlioblastomaCell Biochemistry and Biophysics, 72
A. Veldt, K. Eechoute, H. Gelderblom, J. Gietema, H. Guchelaar, N. Erp, A. Eertwegh, J. Haanen, R. Mathijssen, J. Wessels (2010)
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with SunitinibClinical Cancer Research, 17
M. Huls, F. Russel, R. Masereeuw (2009)
The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ RegenerationJournal of Pharmacology and Experimental Therapeutics, 328
A. Bex, L. Albiges, B. Ljungberg, K. Bensalah, S. Dabestani, R. Giles, F. Hofmann, M. Hora, M. Kuczyk, Thomas Lamk, Lorenzo Marconim, A. Merseburger, M. Staehler, A. Volpe, T. Powles (2016)
European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma
T. Namisaki, E. Schaeffeler, H. Fukui, H. Yoshiji, Y. Nakajima, P. Fritz, M. Schwab, A. Nies, M. Fischer-Bosch (2014)
Running Title Page Running Title : Expression of drug uptake and efflux transporters in HCC
D. Hanahan, R. Weinberg (2011)
Hallmarks of Cancer: The Next GenerationCell, 144
E. Turrini, S. Haenisch, Sandra Laechelt, Tobias Diewock, O. Bruhn, I. Cascorbi (2012)
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expressionPharmacogenetics and Genomics, 22
The efflux transporter breast cancer resistance protein BCRP/ABCG2 is well‐known for its contribution to multi‐drug resistance in cancer. Its relevance in cancer biology independent from drug efflux remains largely elusive. Our study aimed at elucidating the biological relevance and regulatory mechanisms of BCRP/ABCG2 in clear cell renal cell carcinoma (ccRCC) and disease progression. Two independent ccRCC‐cohorts [Cohort 1 (KIRC/TCGA): n = 453, Cohort 2: n = 64] were investigated to elucidate BCRP/ABCG2 mRNA and protein expression and their association with survival. The impact of BCRP/ABCG2 on response to sunitinib treatment was investigated in two independent sunitinib‐treated ccRCC‐cohorts based on mRNA levels. Moreover, underlying regulatory mechanisms for interindividual variability of BCRP/ABCG2 expression were systematically assessed. Owing to redundant functional properties, mRNA and protein expression of the multidrug resistance protein MDR1/ABCB1 were additionally evaluated in these cohorts. In independent ccRCC‐cohorts, low BCRP/ABCG2 and MDR1/ABCB1 mRNA and protein expression were associated with severity (e.g., tumor stage) of ccRCC and poor cancer‐specific survival. BCRP/ABCG2 and MDR1/ABCB1 mRNA expression were linked to decreased progression‐free survival after sunitinib treatment. Germline and somatic variants influenced interindividual variability of BCRP/ABCG2 expression only moderately. miR‐212‐3p and miR‐132‐3p were identified to regulate BCRP/ABCG2 posttranscriptionally by interaction with the ABCG2 3′UTR as confirmed through reporter gene assays in RCC cell lines. In summary, BCRP/ABCG2 expression in ccRCC underlies considerable interindividual variability with impact on patient survival and response to sunitinib treatment. While germline or somatic genetic variants and DNA methylation cannot explain aberrant BCRP/ABCG2 expression, miR‐212‐3p and miR‐132‐3p were identified to contribute to posttranscriptional regulation of BCRP/ABCG2.
International Journal of Cancer – Wiley
Published: Mar 15, 2019
Keywords: ; ; ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.